EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Lotus Pharmaceuticals, Inc (LTUS) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Lotus Pharmaceuticals, Inc $0.00, price $0.00, upside +5.7%, quality 58 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Financial Services · US · ISIN US5457152032

LP Lotus Pharmaceuticals, Inc logo Thin data Oct 3, 2026

Lotus Pharmaceuticals, Inc

LTUS · US

NeutralThe stock looks roughly fairly valued with average quality.

Ranks above peers (8/8)
Fair value $0.0047 · Fairly valued (+5.7%)
Quality 58/100
Mixed Growth (revenue YoY +28.7 %/yr in USD)
Thin margins · 2.4% net margin (TTM)
Negative equity (buybacks among others)
Negative free cash flow
Narrow moat 23/100
Thin data
Watch Lotus Pharmaceuticals, Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.0479 $0.0006 Fair Value $0.0047 Jun 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range $0.0006 – $0.0479 · the $0.0044 price screens below the $0.0047 fair value. Dashed = 300-day average. As of Oct 3, 2026.

Follow Lotus Pharmaceuticals in your weekly email

Every Wednesday you see whether Lotus Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company was formerly known as S.E. Asia Trading, Inc. and changed its name to Lotus Pharmaceuticals, Inc. in December 2006. Lotus Pharmaceuticals, Inc.

Show more

Lotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company was formerly known as S.E. Asia Trading, Inc. and changed its name to Lotus Pharmaceuticals, Inc. in December 2006. Lotus Pharmaceuticals, Inc. is based in Irvine, California.

Stock analysis

Lotus Pharmaceuticals, Inc (LTUS) currently trades at $0.0044, while our model-based Fair Value estimate is $0.0047, so the stock looks roughly fairly valued today (gap 5.4%).

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the evidence level at low.

Quality & growth

The Quality Score stands at 58/100 (solid quality), in the Financial Services sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Lotus Pharmaceuticals, Inc reported revenue of $72.7M in FY2010 versus $36.2M in FY2006, a compound +19.0%/yr. Reported net income was −$29.0K in FY2025.

Key figures

Market cap $11.6M · P/S ratio 0.16 · EPS (TTM) $−0.0400 · Net margin 2.4% · Return on equity 1.8% · Return on assets (EBIT) −389% · Operating margin 6.7% · Revenue (TTM) $71.4M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).

What moves the price

The share trades about 32% below its 52-week high and 144% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Financial Services peers we cover trades at −18% fair-value upside, at 6%, LTUS screens cheaper than that median.

Fair Value models

Bear $0.0047 Fair Value $0.0047 Bull $0.0047
Price $0.0044 · Upside +5.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EV/EBITDA $0.0100 $0.0100 $0.0100 67
All 1 models by family
Multiples
EV/EBITDA $0.0100 $0.0100 $0.0100 67

Open the full fair value analysis →

Notify me when LTUS reaches fair value

Put LTUS on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 58/100

Of which business quality 58 · Market factors (momentum, volatility) 39

Profitability 53
Margins and returns on capital today
Quality Growth 54
Are margins and returns improving?
Cashflow 35
Earnings quality: real cash, not paper profit
Fin. Strength 67
Balance sheet, leverage, solvency risk
Investment 50
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 42
Price trend over the last 3–12 months (market factor)
52W Momentum 21
Distance to the 52-week high (market factor)
Net Issuance 94
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 50/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−0.3% (2004) → 34.2% (2009)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch LTUS, get fair value alerts →

Compare Lotus Pharmaceuticals, Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Shell Companies · 65 stocks

Beats the industry median on 8/8 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 58 · Above median
Fair Value upside +5.7% · Above median
Profitability
Return on equity (TTM) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets 4.6% · Top 25%
Net margin (TTM) 2.4% · Above median
Operating margin (TTM) 6.7% · Top 25%
Growth and dividend
Revenue growth 4.0% · Top 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Shell Companies median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM) 0.16× · Cheaper than median
EV/EBITDA 1.6× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)41 · sector 33
FUTURE (revenue growth)20 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 100
DIVIDEND (yield)0 · sector 0

PAST 0: with negative equity (buybacks among others) return on equity is not meaningfully computable.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Shell Companies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Lionheart III Corp LION $10.85 $14.94 +38%
AA Mission Acquisition Corp AAM $0.0350 $0.0473 +35%
Berto Acquisition Corp TACO $10.46 $2.73 −74%
Metals Acquisition Corp MTAL $10.16 $20.32 +100%
Axiom Intelligence Acquisition Corp AXIN $10.35 $1.71 −83%
JONE JONE $9.82 $19.64 +100%
Bold Eagle Acquisition Corp BEAG $10.71 $4.00 −63%
Lionheart Holdings CUB $10.90 $5.41 −50%
Translational Development Acquisition Corp TDAC $10.85 $4.28 −61%
TGE Value Creative Solutions Corp BEBE $10.04 $8.20 −18%

Explore undervalued stocks

More undervalued Financial Services stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Lotus Pharmaceuticals, Inc · Fair Value
$0.0047 +5%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Lotus Pharmaceuticals, Inc Fair Value". https://www.fairvalue-calculator.com/stock/LTUS

Frequently asked questions

Is Lotus Pharmaceuticals, Inc (LTUS) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of $0.0047 versus a price of $0.0044, about +6% upside (fairly valued).
What is the fair value of LTUS?
Our model-based fair value for Lotus Pharmaceuticals, Inc is $0.0047 (as of Oct 3, 2026), built from audited fundamentals. The current price: $0.0044.
What is the quality score of LTUS?
Lotus Pharmaceuticals, Inc has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Lotus Pharmaceuticals, Inc (LTUS)?
Our model-based price target is the fair value of $0.0047 (as of Oct 3, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Lotus Pharmaceuticals, Inc stock forecast for 2026?
Our models put fair value at $0.0047, about +6% upside versus a price of $0.0044 (fairly valued). The calculation is refreshed regularly with new filings.
What is the revenue of Lotus Pharmaceuticals, Inc (LTUS)?
Lotus Pharmaceuticals, Inc reported trailing-twelve-month revenue of about $71.4M (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Lotus Pharmaceuticals, Inc (LTUS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Lotus Pharmaceuticals, Inc it is $0.0047 per share (as of Oct 3, 2026), against a price of $0.0044. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Lotus Pharmaceuticals, Inc stock overvalued or undervalued in 2026?
As of Oct 3, 2026, LTUS trades below its calculated fair value: price $0.0044, fair value $0.0047, a gap of about +6% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LTUS?
No. The price is what the market pays today ($0.0044); the fair value is what the company's own numbers justify ($0.0047). For Lotus Pharmaceuticals, Inc the two are $0.0002 per share apart. That gap is exactly why we show both numbers side by side.
How much is Lotus Pharmaceuticals, Inc worth?
The market values Lotus Pharmaceuticals, Inc at about $11.6M (market capitalisation, as of Oct 3, 2026). Per share that is $0.0044; our models calculate a fair value of $0.0047 per share.
How solid is the balance sheet of Lotus Pharmaceuticals, Inc (LTUS)?
Balance-sheet figures for Lotus Pharmaceuticals, Inc (as of Oct 3, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is LTUS from its 52-week high?
Lotus Pharmaceuticals, Inc trades at $0.0044, about 32% below its 52-week high of $0.0065 and 144% above the low of $0.0018 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0047 is for.
Which stocks are comparable to Lotus Pharmaceuticals, Inc?
From the same area (Financial Services) we also value Lionheart III Corp, AA Mission Acquisition Corp, Berto Acquisition Corp, Metals Acquisition Corp, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Lotus Pharmaceuticals, Inc stock attractive at the current price?
The data as of Oct 3, 2026: price $0.0044, calculated fair value $0.0047 (+6%), Quality Score 58/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LTUS calculated?
We run Lotus Pharmaceuticals, Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0047, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Lotus Pharmaceuticals, Inc currently trades 5 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Lotus Pharmaceuticals, Inc (LTUS)?
The closing price on Oct 2, 2026 was $0.0044. Our model-based fair value is $0.0047, about +6% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Lotus Pharmaceuticals, Inc right now?
The price is below even our cautious bear case ($0.0047). The market is more pessimistic than our downside scenario. The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.

Key figures of Lotus Pharmaceuticals, Inc

How large is the market capitalisation of Lotus Pharmaceuticals, Inc (LTUS)?
The market capitalisation of Lotus Pharmaceuticals, Inc is $11.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Lotus Pharmaceuticals, Inc (LTUS)?
The price-to-sales ratio of Lotus Pharmaceuticals, Inc is 0.16 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Lotus Pharmaceuticals, Inc (LTUS)?
Earnings per share at Lotus Pharmaceuticals, Inc are $−0.0400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Lotus Pharmaceuticals, Inc (LTUS)?
The net margin of Lotus Pharmaceuticals, Inc is 2.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Lotus Pharmaceuticals, Inc (LTUS)?
The return on equity (ROE) of Lotus Pharmaceuticals, Inc is 1.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Lotus Pharmaceuticals, Inc (LTUS)?
On an EBIT basis the return on assets of Lotus Pharmaceuticals, Inc is −389% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Lotus Pharmaceuticals, Inc (LTUS)?
The operating margin of Lotus Pharmaceuticals, Inc is 6.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Lotus Pharmaceuticals, Inc (LTUS)?
Revenue at Lotus Pharmaceuticals, Inc is growing +4.0% versus a year earlier (3y avg +8.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Lotus Pharmaceuticals, Inc (LTUS)?
Earnings per share at Lotus Pharmaceuticals, Inc are growing −82.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Lotus Pharmaceuticals, Inc (LTUS) generate?
The free cash flow of Lotus Pharmaceuticals, Inc is −$19.1K (fiscal year 2023). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Lotus Pharmaceuticals, Inc (LTUS) carry?
The net debt of Lotus Pharmaceuticals, Inc is $115K (fiscal year 2023). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Lotus Pharmaceuticals, Inc in the live analysis

One click puts Lotus Pharmaceuticals, Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.